Agnes Lteif

600 total citations
16 papers, 300 citations indexed

About

Agnes Lteif is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Agnes Lteif has authored 16 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Agnes Lteif's work include Advanced Breast Cancer Therapies (15 papers), Cancer Treatment and Pharmacology (6 papers) and HER2/EGFR in Cancer Research (4 papers). Agnes Lteif is often cited by papers focused on Advanced Breast Cancer Therapies (15 papers), Cancer Treatment and Pharmacology (6 papers) and HER2/EGFR in Cancer Research (4 papers). Agnes Lteif collaborates with scholars based in United States, Spain and France. Agnes Lteif's co-authors include Nadia Solovieff, Naveen Babbar, Fabrice André, Aleix Prat, Anwesha Chaudhury, Eduardo Martínez de Dueñas, Fei Su, Fara Brasó‐Maristany, Tetiana Taran and Laia Paré and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Agnes Lteif

15 papers receiving 297 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Agnes Lteif United States 7 195 182 102 97 58 16 300
Juan Antonio Barrera Spain 5 106 0.5× 161 0.9× 132 1.3× 151 1.6× 25 0.4× 7 299
Satoshi Hashigaki Japan 11 279 1.4× 306 1.7× 42 0.4× 56 0.6× 111 1.9× 19 406
Michela Palleschi Italy 9 133 0.7× 189 1.0× 75 0.7× 75 0.8× 41 0.7× 46 281
Mengxi Ge China 8 183 0.9× 144 0.8× 108 1.1× 97 1.0× 30 0.5× 15 281
Elshad Hasanov United States 10 157 0.8× 105 0.6× 109 1.1× 171 1.8× 21 0.4× 36 323
Megan E. Lampron United States 6 286 1.5× 217 1.2× 152 1.5× 181 1.9× 39 0.7× 8 448
Andrew Foxley United Kingdom 8 275 1.4× 211 1.2× 112 1.1× 192 2.0× 54 0.9× 20 385
Ligang Niu China 4 138 0.7× 220 1.2× 121 1.2× 100 1.0× 17 0.3× 5 343
Selena Dixon United Kingdom 2 159 0.8× 70 0.4× 77 0.8× 105 1.1× 12 0.2× 7 248
Dina Sakaeva Russia 9 88 0.5× 165 0.9× 48 0.5× 96 1.0× 15 0.3× 44 267

Countries citing papers authored by Agnes Lteif

Since Specialization
Citations

This map shows the geographic impact of Agnes Lteif's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Agnes Lteif with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Agnes Lteif more than expected).

Fields of papers citing papers by Agnes Lteif

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Agnes Lteif. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Agnes Lteif. The network helps show where Agnes Lteif may publish in the future.

Co-authorship network of co-authors of Agnes Lteif

This figure shows the co-authorship network connecting the top 25 collaborators of Agnes Lteif. A scholar is included among the top collaborators of Agnes Lteif based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Agnes Lteif. Agnes Lteif is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Curigliano, Giuseppe, Eva Ciruelos, Kevin Kalinsky, et al.. (2024). Short-term risk of recurrence in patients (pts) with HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): A meta-analysis.. Journal of Clinical Oncology. 42(16_suppl). 541–541. 9 indexed citations
2.
3.
Prat, Aleix, Nadia Solovieff, Fabrice André, et al.. (2023). Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7. Clinical Cancer Research. 30(4). 793–802. 8 indexed citations
4.
André, Fabrice, Faye Su, Nadia Solovieff, et al.. (2023). Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Annals of Oncology. 34(11). 1003–1014. 43 indexed citations
5.
6.
Prat, Aleix, Nadia Solovieff, Faye Su, et al.. (2022). Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies. Cancer Research. 82(4_Supplement). PD2–5. 3 indexed citations
7.
8.
Laurentiis, Michelino De, Matteo Lambertini, Stephen Chia, et al.. (2022). Abstract P1-18-11: Analysis of first-line (1L) patients (pts) with de novo disease vs late relapse and all pts with vs without prior chemotherapy (CT) in the MONALEESA-3 (ML-3) trial. Cancer Research. 82(4_Supplement). P1–18. 1 indexed citations
9.
Prat, Aleix, Anwesha Chaudhury, Nadia Solovieff, et al.. (2021). Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. Journal of Clinical Oncology. 39(13). 1458–1467. 90 indexed citations
10.
Rugo, Hope S., Fabrice André, Toshinari Yamashita, et al.. (2020). Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Annals of Oncology. 31(8). 1001–1010. 113 indexed citations
11.
Laurentiis, Michelino De, Luis de la Cruz‐Merino, Aditya Bardia, et al.. (2020). 331P Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA (ML) -3 and -7. Annals of Oncology. 31. S378–S379. 3 indexed citations
12.
Hurvitz, Sara A., Guy Jérusalem, S-A. Im, et al.. (2020). 329P Ribociclib (RIB) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and resistance to prior endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials. Annals of Oncology. 31. S376–S377. 3 indexed citations
13.
14.
Mayer, Ingrid A., Hope S. Rugo, Sibylle Loibl, et al.. (2019). Patient-reported outcomes (PROs) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from SOLAR-1.. Journal of Clinical Oncology. 37(15_suppl). 1039–1039. 3 indexed citations
15.
16.
Lteif, Agnes, et al.. (2009). Treatment of Familial Male-limited Precocious Puberty (Testotoxicosis) with Anastrozole and Bicalutamide in a Boy with a Novel Mutation in the Luteinizing Hormone Receptor. Journal of Pediatric Endocrinology and Metabolism. 22(12). 1163–7. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Juan Antonio Barrera Breakdown of academic impact, for papers by Satoshi Hashigaki Breakdown of academic impact, for papers by Michela Palleschi Breakdown of academic impact, for papers by Mengxi Ge Breakdown of academic impact, for papers by Elshad Hasanov Breakdown of academic impact, for papers by Megan E. Lampron Breakdown of academic impact, for papers by Andrew Foxley Breakdown of academic impact, for papers by Ligang Niu Breakdown of academic impact, for papers by Selena Dixon Breakdown of academic impact, for papers by Dina Sakaeva
Rankless by CCL
2026